CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears
CAPR stock is on track for its worst month since July, with a November FDA decision on deramiocel approaching. Analysts have mixed ratings, with an average 12-month price target of $27, implying over 300% upside from Tuesday's close. Retail sentiment on Stocktwits has shifted from extremely bullish to bullish, with mixed opinions on the stock's potential. CAPR stock has fallen about 80% year-to-date.
How this was made
The 30-second read
Why it matters
The piece offers no actionable catalyst; it merely restates existing sentiment and price targets.
Market read
Low relevance; serves as a sentiment recap for existing investors.
What to watch
Potential upcoming FDA decision on Deramiocel could change dynamics, but not disclosed in this article.
Background
CAPR is a biotech focused on dermatology; the article aggregates analyst ratings and Stocktwits sentiment without new corporate disclosures.
Ticker impact
Analyst coverage shows 4 buys vs 6 holds and a 12‑month price target of $27, while retail sentiment on Stocktwits turned bearish and the stock has fallen ~80% YTD.
likely further decline as traders react to bearish sentiment and low analyst ratings
No new corporate event; the article only recaps existing analyst ratings and retail sentiment, which are already reflected in the stock's steep decline.
Market effects
Limited; reflects broader biotech sentiment but no sector‑wide catalyst.
Minimal; impact confined to CAPR investors.
Low
Counterpoint
Despite weak sentiment, the $27 target implies >300% upside if a breakthrough trial succeeds.
Key entities
- companyCAPR
Capricor Therapeutics, NASDAQ:CAPR
